Company research
aTYR PHARMA INC
CIK 1339970Updated Sep 27, 2026
SecurityATYR · NASDAQ · equity
ATYR price & chart
Loading TradingView…
NASDAQ:ATYR on TradingView ↗About the company
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its
In the news
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Dec 08, 2025, 20:59 ET Share this article Share to X Share this article Share to X NEW YORK , Dec. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a g ↗
Seeking Alpha
aTyr Pharma GAAP EPS of -$0.11 beats by $0.04 ↗
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results - Slideshow ↗
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript ↗
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Termination of a Material Definitive Agreement
Items 1.02, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 93,003,000Source | 96,830,000Source | 120,653,000Source | 95,786,000Source |
| Property, Plant and Equipment, NetUSD | 4,263,000Source | 4,850,000Source | 5,531,000Source | 3,059,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,743,000Source | 11,055,000Source | 22,544,000Source | 9,981,000Source |
| Assets, CurrentUSD | 80,237,000Source | 81,954,000Source | 102,992,000Source | 80,871,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,524,000Source | 5,817,000Source | 6,727,000Source | 7,250,000Source |
| Other Assets, NoncurrentUSD | 148,000Source | 66,000Source | 131,000Source | 193,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 98,000Source | 84,000Source | 63,000Source | 29,000Source |
| Additional Paid in CapitalUSD | 673,554,000Source | 602,021,000Source | 558,692,000Source | 489,502,000Source |
| Retained Earnings (Accumulated Deficit)USD | -606,164,000Source | -532,046,000Source | -468,023,000Source | -417,634,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -8,000Source | -40,000Source | -74,000Source | -433,000Source |
| Stockholders' Equity Attributable to ParentUSD | 67,480,000Source | 70,019,000Source | 90,658,000Source | 71,464,000Source |
| Liabilities and EquityUSD | 93,003,000Source | 96,830,000Source | 120,653,000Source | 95,786,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 15,148,000Source | 14,967,000Source | 16,416,000Source | 13,862,000Source |
| Operating Lease, Liability, CurrentUSD | 836,000Source | 711,000Source | 831,000Source | 630,000Source |
| Accounts Payable, CurrentUSD | 3,891,000Source | 4,323,000Source | 3,529,000Source | 3,106,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,308,000Source | 11,144,000Source | 12,339,000Source | 9,633,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -192,000Source | -187,000Source | -188,000Source | -180,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,791,000Source | 9,392,000Source | 11,559,000Source | 9,862,000Source |
| Deferred Tax Liabilities, NetUSD | 1,160,000Source | 1,223,000Source | 1,414,000Source | 1,524,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -74,123,000Source | -64,022,000Source | -50,397,000Source | -45,343,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 664,000Source | 708,000Source | 592,000Source | 232,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -61,986,000Source | -69,119,000Source | -33,221,000Source | -41,886,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,053,000Source | 17,233,000Source | -20,127,000Source | 47,245,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 77,000Source | 65,000Source | 4,215,000Source | 1,641,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 66,011,000Source | 39,864,000Source | 66,230,000Source | 5,451,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,028,000Source | -12,022,000Source | 12,882,000Source | 10,810,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 94,000Source | 137,000Source | 172,000Source | 54,000Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | 4,997,000Source | 2,989,000Source | 2,600,000Source | 2,154,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 12,000Source | 3,000Source | 6,000Source | 92,000Source |
| General and Administrative ExpenseUSD | 17,598,000Source | 13,777,000Source | 12,979,000Source | 13,982,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -74,118,000Source | -64,023,000Source | -50,389,000Source | -45,338,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -5,000Source | 1,000Source | -8,000Source | -5,000Source |
| Nonoperating Income (Expense)USD | 3,504,000Source | 3,892,000Source | 4,522,000Source | 1,061,000Source |
| Operating ExpensesUSD | 77,817,000Source | 68,149,000Source | 55,272,000Source | 56,790,000Source |
| Operating Lease, ExpenseUSD | 1,500,000Source | 1,500,000Source | 1,900,000Source | 1,500,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 190,000Source | 235,000Source | 353,000Source | 10,386,000Source |
| Operating Income (Loss)USD | -77,627,000Source | -67,914,000Source | -54,919,000Source | -46,404,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -74,123,000Source | -64,022,000Source | -50,395,000Source | -45,340,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -5,000Source | 1,000Source | -8,000Source | -5,000Source |
| Net Income (Loss) Attributable to ParentUSD | -74,118,000Source | -64,023,000Source | -50,389,000Source | -45,338,000Source |
| Earnings Per Share, BasicUSD per share | -0.8Source | -0.86Source | -0.94Source | -1.6Source |
| Earnings Per Share, DilutedUSD per share | -0.8Source | -0.86Source | -0.94Source | -1.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 92,985,359Source | 74,261,265Source | 53,606,488Source | 28,419,569Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 92,985,359Source | 74,261,265Source | 53,606,488Source | 28,419,569Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 17,598,000Source | 13,777,000Source | 12,979,000Source | 13,982,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -73,891,000Source | -64,086,000Source | -49,967,000Source | -45,086,000Source |
| Nonoperating Income (Expense)USD | 3,504,000Source | 3,892,000Source | 4,522,000Source | 1,061,000Source |
| Operating ExpensesUSD | 77,817,000Source | 68,149,000Source | 55,272,000Source | 56,790,000Source |
| Operating Lease, ExpenseUSD | 1,500,000Source | 1,500,000Source | 1,900,000Source | 1,500,000Source |
| Other General and Administrative ExpenseUSD | 13,730,000Source | 11,402,000Source | — | — |
| Research and Development ExpenseUSD | 60,219,000Source | 54,372,000Source | 42,293,000Source | 42,808,000Source |
Filing attachments
atyr-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of a…
Read attachment ↗atyr-ex99_1.htm · 8-K · 2026-07-31
EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Agreement”) is made and entered into as of July 30, 2026 (“Execution Date”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121, USA (“aTyr”), and Kyorin Pharmaceutical Co., Ltd., a Japanese corporation, having its principal place of business at 1-3-7, Otemachi, Chiyoda-ku,…
Read attachment ↗atyr-ex99_1.htm · 8-K · 2026-06-01
EX-99.1 2 atyr-ex99_1.htm EX-99.1 aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond June 2026 © 2026 aTyr Pharma Exhibit 99.1 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “b…
Read attachment ↗atyr-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis…
Read attachment ↗atyr-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 atyr-ex99_1.htm EX-99.1 aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,”…
Read attachment ↗atyr-ex99_1.htm · 8-K · 2026-03-05
EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in syste…
Read attachment ↗